20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Aura Biosciences Inc (AURA) operates in the BIOTECHNOLOGY industry and is headquartered in Boston, United States with about 113 employees. Its market capitalization is roughly $647 million. In the fiscal year ended 2025-12-31, AURA reported $0M in revenue and ($106M) in net income.
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | — | ($1M) | ($1M) | ($1M) | ($1M) | ($1M) | ($1M) |
| Gross Margin % | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($138M) | ($113M) | ($96M) | ($85M) | ($60M) | ($35M) | ($22M) | ($24M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | ($131M) | ($106M) | ($87M) | ($76M) | ($59M) | ($35M) | ($22M) | ($24M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | ($132M) | ($105M) | ($86M) | ($75M) | ($58M) | ($34M) | ($21M) | ($24M) |
| Earnings Per Share (EPS) | $-1.80 | $-1.76 | $-1.75 | $-1.93 | $-1.96 | $-1.21 | $-0.76 | $-0.01 |
| Shares Outstanding (M) | 95M | 60M | 50M | 40M | 30M | 29M | — | 2,922M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $1M | $0M |
| Gross Profit | — | $0M | $1M | $0M | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | -23.5% | — |
| Operating Income (EBIT) | ($48M) | ($35M) | ($27M) | ($28M) | ($29M) | ($29M) | ($28M) | ($23M) |
| Operating Margin % | — | — | — | — | — | — | -2246.1% | — |
| Net Income | ($46M) | ($34M) | ($26M) | ($26M) | ($27M) | ($27M) | ($26M) | ($21M) |
| Net Margin % | — | — | — | — | — | — | -2086.8% | — |
| EBITDA | ($48M) | ($32M) | ($25M) | ($26M) | ($27M) | ($27M) | ($28M) | ($21M) |
| Earnings Per Share (EPS) | $-0.48 | $-0.50 | $-0.42 | $-0.40 | $-0.47 | $-0.55 | $-0.52 | $-0.42 |
| Shares Outstanding (M) | 95M | 67M | 60M | 66M | 58M | 50M | 50M | 50M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($102M) | ($85M) | ($80M) | ($64M) | ($55M) | ($32M) | ($24M) | ($21M) |
| Capital Expenditures (CapEx) | $0M | $0M | $1M | $1M | $1M | $2M | $1M | $2M |
| Free Cash Flow (FCF) | ($103M) | ($85M) | ($81M) | ($65M) | ($56M) | ($35M) | ($25M) | ($23M) |
| FCF Margin % | — | — | — | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — | — | — | $40M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($32M) | ($30M) | ($20M) | ($20M) | ($21M) | ($23M) | ($24M) | ($15M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($32M) | ($30M) | ($21M) | ($20M) | ($21M) | ($24M) | ($24M) | ($16M) |
| FCF Margin % | — | — | — | — | — | — | -1958.9% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $348M | $169M | $183M | $255M | $224M | $160M | $22M | $37M |
| Cash & Cash Equivalents | $68M | $60M | $32M | $41M | $122M | $149M | $17M | $32M |
| Total Liabilities | $33M | $33M | $31M | $29M | $28M | $8M | $3M | $6M |
| Total Debt (Short + Long-Term) | $3M | $3M | $3M | $3M | $3M | $1M | $0M | $0M |
| Total Shareholders' Equity | $315M | $137M | $152M | $226M | $196M | $152M | $19M | $31M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AURA viewer.
About TickerBase · Data methodology & sources · Privacy · Terms